Compare Exelixis Inc. Common Stock (EXEL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $61.44 (market cap $15.12B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Exelixis Inc. Common Stock is far larger — about 15.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 3 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXEL | MRVI | |
|---|---|---|
Market Cap | $15.12B | $977.37M |
Volume | 2,752,905 | 2,742,564 |
Sector | Health | Health |
52-Week High | $60.99 | $9.00 |
52-Week Low | $34.54 | $2.83 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $14.44B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.
The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
